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Introduction
============

Oral squamous cell carcinoma (OSCC) is ranked as the eighth most common cancer, with global incidence being 299,050 and 12,720 in Pakistan in 2012 \[[@REF1]\]. An alarming statistic is that Karachi, the largest city of Pakistan, bears the highest incidence of oral cavity cancer in the world \[[@REF2]\]. Moreover, a study conducted in Karachi stated that OSCC among low-income families had increased by 200% from 1998 to 2002. According to the reports published by Pakistan Medical Research Council (PMRC), OSCC is the most common cancer among males and ranks second highest among females \[[@REF3]\]. The worldwide mortality for 2012 was 145,350, stressing upon the need for effective management of the disease.

Emphasizing on the importance of this disease and its devastating consequences on our population, research in the developmental mechanisms of OSCC holds immense importance. The progress of OSCC at the molecular level is still unclear but latest developments present it to be the result of environmental factors causing mutations in oncogenes and tumor suppressor genes, particularly those involved in cell proliferation, differentiation, apoptosis and deoxyribonucleic acid (DNA) repair \[[@REF4]\].

Several risk factors are known to aid in the pathogenesis of OSCC: smoking, alcohol consumption, chewing of betel quid and areca nut, and human papillomavirus infection \[[@REF5]\]. Approximately 600 million people engage in betel quid chewing worldwide \[[@REF5]\], making it the fourth most common addictive substance used, following tobacco, alcohol, and caffeine \[[@REF6]\]. A study piloted in a squatter settlement of Karachi exposed that 40% of the population used betel nut and tobacco regularly \[[@REF7]\].

Among all the mutations found in OSCC, the TP53 tumor suppressor gene is most frequently mutated \[[@REF8]-[@REF9]\]. The TP53 gene is located on the short arm of chromosome 17 and prevents cancer formation by maintaining genomic stability and regulating the cell cycle. Different kinds of stresses including oncogenic stimuli, ionizing radiation, UV radiation, hypoxia, cytokines and growth factors can activate the TP53 through different pathways \[[@REF10]\]. As the "guardian of the genome"- p53 protein can initiate DNA repair proteins and stop the cell cycle at the G1/S regulation point when the DNA is damaged or activate apoptosis if the DNA is damaged beyond repair. When mutated, it allows cells to progress through DNA damage checkpoints and these cells are allowed to replicate along with their harmful mutations.

It has been established by the International Cancer Genome Consortium that the missense mutation is the most commonly occurring type (79%) among all TP53 mutations \[[@REF11]\]. Mutations in TP53 make it more stable and hence easy to detect by immunohistochemistry \[[@REF12]\]. However, any loss-of-function mutation in the TP53 does not directly transform the cells into neoplastic cells as loss of guardian function has no direct effect on proliferation. Instead, it permits the DNA to get damaged easily leading to mutations, acquisition of oncogenes, and neoplastic activity.

To date, even after intense research in management options, the five-year survival rate for OSCC has not increased significantly \[[@REF13]\]. There have been very few studies on OSCC five-year survival worldwide and no studies to date in Pakistan, to the best of our knowledge. There have been a number of studies on one- and two-year survival but it is difficult to use such data to form conclusions in cancers like OSCC as these patients usually live for up to more than two years which stresses the need for five-year survival studies. Furthermore, the association of TP53 mutation and five-year survival of OSCC patients is still unclear. Correlation of TP53 mutation with gender, age, OSCC risk factors like alcohol and tobacco, site and grading are currently being established in different researches around the world in order to provide detailed information on OSCC patient prognosis at the time of presentation.

We have previously carried out and published a study discussing TP53 expression in terms of overall survival which concerned the same patient data set \[[@REF14]\]. Five-year follow-up data for these patients was unavailable at the time of that study, as they had been freshly recruited, thus the aim of that study was to understand TP53 expression in terms of overall survival, as the duration of survival varied greatly among the patients. Subsequently, the aim of this study is to continue work on these patients and establish any and all such correlations between TP53 mutation and OSCC patient prognosis using a fixed five-year survival rate as it is the optimum method to validate prognostic use of any marker.

Materials and methods
=====================

The study was a case series including 140 patients with primary OSCC who had been diagnosed and treated at Aga Khan University Hospital (AKUH), Karachi, Pakistan from January 2000 to January 2008. The study was approved by the Ethical Review Committee at AKUH and written informed consent was taken from all patients prior to their induction in the study. Inclusion criteria consisted of complete clinicopathologic data and presence of five-year follow-up data. Clinicopathologic information on each case including gender, age, TP53 overexpression, use of betel nut and/or other substances, smoking or alcohol consumption either alone or in different combinations, the site of OSCC, American Joint Committee on Cancer (AJCC) staging, tumor size, nodal involvement and metastasis was collected from our previously conducted study \[[@REF14]\]. Additional five-year follow-up was obtained for all patients and they were classified as either alive or dead after 60 months. Immunohistochemistry was used in our previously reported study to assess TP53 overexpression using primary antibody TP53 (mouse monoclonal anti-TP53, clone DO-7, Dako Cytomation, diluted 1:50).

The results were recorded by the study investigators and data was analyzed using SPSS version 19 (IBM, NY, USA). Potential associations between demographic, histological, clinical parameters and five-year survival were assessed. Follow-up times for each patient were measured in months and mean survival was calculated from the date of diagnosis until death or for 60 months, whichever occurred sooner. Univariate Cox analysis was done to investigate the effect of clinicopathologic factors on mean five-year survival and a multivariate analysis was done for AJCC staging and TP53 positivity. A Kaplan-Meier curve was plotted to assess the event point distribution over a period of 60 months.

Results
=======

Patient characteristics

The total sample size was 140, with 69 patients expiring (event) and 71 alive (censored) at the end of 60 months. In our study, 82 patients (59%) were males and 58 (41%) were females with a male-female ratio of 1.4:1 and 112 (80%) patients were \>40 years of age. The most frequently occurring primary lesion location was cheek (86) followed by tongue (54), mandible (36), palate (14), retromandible (17) and the floor of the mouth (14). Additionally, the highest number of patients presented with AJCC stage II disease (34%), followed by stage III (27%), stage IV (22%) and stage I (19%). Based on the disease stage, 82 (59%) patients were treated with surgery and radiation both while 58 (41%) were treated with surgery alone. Most commonly used addictive substance for our patients was betel quid, followed by tobacco. Table [1](#TAB1){ref-type="table"} shows the demographic details of the patients.

###### Patient demographics at five-year follow-up (n = 140).

  -------------------------------------- ---------------- ------------------- ----------------- ------- ------------ ------- --------
                                         Event (n = 69)   Censored (n = 71)   Total (n = 140)                                
  Count                                  Column N %       Count               Column N %        Count   Column N %           
  Gender                                 Male             40                  58.0%             42      59.2%        82      58.6%
  Female                                 29               42.0%               29                40.8%   58           41.4%   
  Age group                              \<40 years       11                  15.9%             17      23.9%        28      20.0%
  \>= 40 years                           58               84.1%               54                76.1%   112          80.0%   
  TP53 value                             Positive         49                  71.0%             45      63.4%        94      67.1%
  Negative                               20               29.0%               26                36.6%   46           32.9%   
  Positivity                             Mild             8                   11.6%             11      15.5%        19      13.6%
  Moderate                               15               21.7%               7                 9.9%    22           15.7%   
  Strong                                 26               37.7%               27                38.0%   53           37.9%   
  Negative                               20               29.0%               26                36.6%   46           32.9%   
  Histological classification of tumor   W-D-SCC          26                  37.7%             29      40.8%        55      39.3%
  M-D-SCC                                41               59.4%               38                53.5%   79           56.4%   
  P-D-SCC                                2                2.9%                4                 4.1%    6            4.3%    
  AJCC_STAGE                             I                9                   13.0%             18      25.4%        27      19.3%
  II                                     18               26.1%               26                36.6%   44           31.4%   
  III                                    22               31.9%               16                22.5%   38           27.1%   
  IV                                     20               29.0%               11                15.5%   31           22.1%   
  Smoking                                Yes              26                  37.7%             25      41.7%        51      36.4%
  No                                     43               62.3%               35                58.3%   89           63.6%   
  Betel quid chewer                      Yes              43                  62.3%             39      54.9%        82      58.6%
  No                                     26               37.7%               32                45.1%   48           34.4%   
  Tobacco                                Yes              20                  29.0%             23      32.4%        43      30.7%
  No                                     49               71.0%               48                67.6%   97           69.3%   
  Cheek/tongue                           Cheek            48                  69.6%             38      53.5%        86      61.4%
  Tongue                                 21               30.4%               33                46.5%   54           38.6%   
  Palate                                 Yes              6                   8.7%              8       11.3%        14      10.0%
  No                                     63               91.3%               63                88.7%   126          90.0%   
  Mandible                               Yes              18                  26.1%             18      25.4%        36      25.7%
  No                                     51               73.9%               53                74.6%   104          74.3%   
  Retromandibular                        Yes              11                  15.9%             6       8.5%         17      12.1%
  No                                     48               69.6%               51                71.8%   99           70.7%   
  NA                                     10               14.5%               14                19.7%   24           17.1%   
  Floor of mouth                         Yes              4                   5.8%              10      14.1%        14      10.0%
  No                                     65               94.2%               61                85.9%   126          90.0%   
  Tonsil                                 Yes              1                   1.4%              2       2.8%         3       2.1%
  No                                     68               98.6%               69                97.2%   137          97.9%   
  Nodal status physical                  Palpable node    31                  44.9%             26      36.6%        57      40.7%
  No palpable node                       38               55.1%               45                63.4%   83           59.3%   
  Single/multiple nodes                  Single           20                  29.0%             19      26.8%        39      27.9%
  Multiple                               11               15.9%               7                 9.9%    18           12.9%   
  NA                                     38               55.1%               45                63.3%   83           59.3%   
  Final T stage                          T1               12                  17.4%             21      29.6%        33      23.6%
  T2                                     31               44.9%               33                46.5%   64           45.7%   
  T3                                     12               17.4%               10                14.1%   22           15.7%   
  T4                                     14               20.3%               7                 9.8%    21           15.0%   
  Final N stage                          N0               43                  62.3%             59      83.1%        102     72.9%
  N1                                     18               26.1%               8                 11.3%   26           18.6%   
  N2a                                    2                2.9%                1                 1.4%    3            2.1%    
  N2b                                    6                8.7%                3                 4.2%    9            6.4%    
  Final M stage                          M0               69                  100.0%            71      100.0%       140     100.0%
   Neck pathology                        Negative         27                  39.1%             44      62.0%        71      50.7%
  Positive                               25               36.2%               13                18.3%   38           27.1%   
  ND                                     17               24.6%               14                19.7%   31           22.1%   
  -------------------------------------- ---------------- ------------------- ----------------- ------- ------------ ------- --------

Out of 140 tumors, 94 (67%) patients were TP53 positive and 46 (33%) patients were TP53 negative. TP53 overexpression was not significantly correlated with any clinicopathologic parameters tested, such as AJCC staging, habits, histology and final T and N stages. A total of 54 patients presented with tongue as the primary site of tumor, with 51 patients having tumor in the anterior tongue, five in the posterior and two patients having both. However, a significant association was observed between the anterior tongue as the site of tumor and TP53 positivity (p = 0.038). Table [2](#TAB2){ref-type="table"} shows TP53 expression and clinicopathologic parameters.

###### Correlation of P53 overexpression and clinicopathologic parameters.

  ---------------- --------------------- ----------------------------- ----------------------------- -------------------------- ---------
  Characteristic                         P53 overexpression positive   P53 overexpression negative   Pearson Chi-Square value   p-value
  AJCC staging     Stage I               21                            6                             5.247                      0.155
                   Stage II              33                            11                                                       
                   Stage III             22                            16                                                       
                   Stage IV              18                            13                                                       
  Habits           Smoking/tobacco       35                            16                            0.090                      0.956
                   Pan/supari            57                            25                            0.612                      0.736
                   Naswar/chalia/gutka   28                            15                            0.242                      0.886
  Final T stage    Stage I               23                            10                            4.439                      0.218
                   Stage II              47                            17                                                       
                   Stage III             11                            11                                                       
                   Stage IV              13                            8                                                        
  Final N stage    N0                    70                            32                            0.560                      0.756
                   N1                    17                            9                                                        
                   N2                    7                             5                                                        
  Histology        W-D-SCC               38                            17                            0.894                      0.640
                   M-D-SCC               53                            26                                                       
                   P-D-SCC               3                             3                                                        
  Site of tumor    Anterior tongue       30                            23                            4.294                      0.038
                   Posterior tongue      4                             1                             0.389                      0.533
                   Palate                10                            4                             0.130                      0.719
                   Mandible              23                            13                            0.233                      0.630
                   Retromandibular       11                            6                             0.387                      0.824
                   Floor of mouth        9                             5                             0.058                      0.810
                   Tonsil                3                             0                             1.500                      0.221
  ---------------- --------------------- ----------------------------- ----------------------------- -------------------------- ---------

Furthermore, AJCC staging, final N stage and neck pathology were found statistically significant on univariate analysis (p = 0.003, p \< 0.001 and p = 0.003, respectively) (Table [3](#TAB3){ref-type="table"}). Moreover, AJCC staging remained significant (p = 0.003) on multivariate analysis using COX regression, while TP53 persisted statistically insignificant.

Mean and median survival time

AJCC stage I was associated with significantly longer survival (49.9 months, 95% CI: 41.9-57.9) as compared to stage IV (31.8 months, 95% CI: 22.9-40.6) as shown in Table [3](#TAB3){ref-type="table"}. Additionally, the absence of neck pathology displayed significantly longer survival (50.2 months, 95% CI: 45.8-54.5). Table [3](#TAB3){ref-type="table"} shows the univariate and multivariate analysis.

###### Univariate and multivariate analysis.

  ------------------------------ ------------------------ ------------------------------ --------------------- -------- ---------
  [Univariate Analysis]{.ul}                                                                                            
  Factor                         Hazard ratio or Exp(B)   95.0% CI for Exp(B)            Sig.                           
  Lower                          Upper                                                                                  
  TP53 value                     Positive                 1                                                              .265
  Negative                       1.344                    .798                           2.262                          
  AJCC_STAGE                     I                        .326                           .148                  .716     .003
  II                             .361                     .191                           .684                           
  III                            .560                     .305                           1.028                          
  IV                             1                                                                                      
  Final N stage                  N0                       .249                           .105                  .592     \<0.001
  N1                             .560                     .221                           1.417                          
  N2a                            2.573                    .494                           13.385                         
  Neck pathology                 Negative                 .584                           .318                  1.072    .003
  Positive                       1.482                    .799                           2.747                          
  [Multivariate Analysis]{.ul}                                                                                          
                                                          Adjusted hazard ratio Exp(B)   95.0% CI for Exp(B)   Sig.     
                                 Lower                    Upper                                                         
  AJCC_STAGE                                                                                                            .003
  I                              1.114                    0.500                          2.481                          
  II                             1.823                    0.837                          3.972                          
  III                            3.309                    1.497                          7.316                          
  TP53 value                     Positive                  1.543                         0.911                 2.612    .107
  Negative                       1                                                                                      
  ------------------------------ ------------------------ ------------------------------ --------------------- -------- ---------

TP53 positivity and survival

All clinical features in Table [1](#TAB1){ref-type="table"} were examined to determine any correlation with TP53 overexpression using Pearson Chi-square test and it was found that TP53 overexpression was not significantly correlated with any clinicopathologic factor (HR: 1.543; 95% CI: 0.911-2.612, p = 0.107). Additionally, TP53 overexpression was also not statistically significant on univariate analysis (p = 0.265) (Table [3](#TAB3){ref-type="table"}). Furthermore, there was no marked difference in mean survival time of TP53 positive (44.258, 95% CI: 39.918-48.597) and TP53 negative (46.676, 95% CI: 40.314-53.039) patients. Table [4](#TAB4){ref-type="table"} shows mean and median survival time.

###### Mean and median survival time.

  ---------------- ------------- ------------------------- ------------- ------------ ------------------------- -------- -------- --------
                   Mean^a^       Median                                                                                           
  Estimate         Std. error    95% confidence interval   Estimate      Std. error   95% Confidence interval                     
  Lower bound      Upper bound   Lower bound               Upper bound                                                            
  Overall          45.079        1.821                     41.511        48.648       60.000                    .964     58.111   61.889
  TP53 value                                                                                                                       
  Positive         44.258        2.214                     39.918        48.597       60.000                    2.669    54.769   65.231
  Negative         46.676        3.246                     40.314        53.039                                                    
  Positivity                                                                                                                       
  Mild             53.500        3.618                     46.409        60.591       60.000                                       
  Moderate         36.994        4.513                     28.148        45.841       32.000                    3.737    24.676   39.324
  Strong           43.894        3.107                     37.805        49.983       60.000                    4.226    51.717   68.283
  Negative         46.676        3.246                     40.314        53.039                                                    
  AJCC_STAGE                                                                                                                       
  I                49.944        4.093                     41.921        57.967                                                    
  II               51.417        2.432                     46.652        56.183                                                    
  II               44.831        3.397                     38.173        51.488       60.000                    7.122    46.041   73.959
  IV               31.809        4.514                     22.962        40.656       19.000                    9.947    0.000    38.496
  Final T stage                                                                                                                    
  T1               50.711        3.441                     43.966        57.456                                                    
  T2               46.970        2.474                     42.122        51.819       60.000                    1.360    57.335   62.665
  T3               43.905        4.815                     34.468        53.342       60.000                    11.148   38.149   81.851
  T4               32.813        5.390                     22.249        43.376       26.000                    11.006   4.429    47.571
  Final N stage                                                                                                                    
  N0               49.019        1.938                     45.220        52.818                                                    
  N1               37.211        4.386                     28.614        45.808       32.000                    4.718    22.753   41.247
  N2a              12.500        .500                      11.520        13.480       12.000                                       
  N2b              28.857        8.385                     12.423        45.292       19.000                    6.547    6.169    31.831
  Neck pathology                                                                                                                   
  Negative         50.211        2.208                     45.884        54.539                                                    
  Positive         37.573        3.880                     29.969        45.178       40.000                    7.767    24.776   55.224
  ND               42.464        4.081                     34.465        50.462       60.000                    11.262   37.927   82.073
  ---------------- ------------- ------------------------- ------------- ------------ ------------------------- -------- -------- --------

However, mild degree of positivity was found to be associated with longer survival (53.5, CI: 46.4-60.6) as compared to moderate degree of positivity (36.99, CI: 28.1-45.8). A Kaplan-Meier curve plotted as shown in Figure [1](#FIG1){ref-type="fig"} for fixed five-year survival illustrated no significant difference in survival between TP53 positive and negative groups with Log Rank 0.239.

![Kaplan-Meier curve depicting five-year survival of p53 positive and negative oral squamous cell carcinoma (OSCC) patients.](cureus-0009-00000001401-i01){#FIG1}

Discussion
==========

The carcinogenesis of the gastrointestinal tract epithelium is an intricate process that involves abnormalities of oncogenes and tumor suppressor genes \[[@REF15]-[@REF16]\]. Even today it is not clear why patients having identical tumor grading and staging behave differently when confronted with similar treatments. This may be due to unique molecular changes resulting from differing expression of certain genes.

Western countries have a high incidence of TP53 mutations in OSCC associated with these risk factors \[[@REF17]\] with India \[[@REF18]\] reported to have low incidence and Taiwan \[[@REF19]\] with high incidence from Asia. We report no association of these risk factors including smoking, tobacco and betel quid usage with TP53 over expression.

Environmental insults are known to be one of the root causes of oral cancer, considering that this malignancy occurs almost exclusively in patients with tobacco, alcohol and/or betel quid usage and these agents are believed to cause a synergistic carcinogenic effect on the oral cavity \[[@REF5]\]. The independent effect of these risk factors is difficult to ascertain considering that most subjects are using a combination of these risk factors and as a result multiple conflicting outcomes have been reported.

Of all related genes, TP53 has received foremost attention: Its prevalence in head and neck squamous cell cancer varies from 30% to 70% \[[@REF20]\]. Almost all types of cancers are reported to have TP53 mutations, from 10% in hematopoietic malignancies to close to 100% in high-grade serous carcinoma of the ovary \[[@REF21]\]. According to "The TP53 website" lung cancers have the highest TP53 mutation rate (70%) followed by colorectal (60%) and head and neck cancers (60%). Laryngeal squamous cell carcinoma is severely implicated in TP53 overexpression and so is the progression of non-malignant lesions to malignant ones, but for the prognostic significance of TP53 and observing its value for the entire head and neck squamous cell cancer group, results differ among studies.

In the past, there have been studies showing no correlation between TP53 expression and patient prognosis, regardless of whether the analysis involved only the invasive fronts of tumors \[[@REF22]\], or tumors as a whole \[[@REF23]\]. On the other hand in a study conducted on 16 patients with recurrent squamous cell carcinoma of the head and neck, a poor prognosis with positive TP53 expression was observed \[[@REF24]\].

The presence of TP53 mutation was associated with a significantly decreased overall survival and even stronger association with disruptive mutations as shown by Poeta, et al. \[[@REF25]\]. However, other multiple attempts have turned out inconclusive in correlating TP53 status and survival. The diversity of results may partly be due to: a diverse and small sample size, the tissue type analyzed and the methods used for analysis including antibodies, tissue treatment and the threshold set for positivity and negativity of stained sections \[[@REF26]\].

In our study we observed that neither the histological differentiation nor the consumption of addictive substances or any other risk factors were associated with TP53 overexpression, only the location of tumor was significant for the anterior tongue showing most TP53 expression. AJCC staging, nodal status, and neck pathology were significantly associated with TP53 overexpression in univariate analysis but lost their significance in the multivariate analysis. This is in accordance with other reports including Field, et al. which reported no correlation between TP53 overexpression and any other clinicopathological parameters \[[@REF27]\]. However, some previous reports \[[@REF17]\] have described accumulating TP53 levels correlating with increasing histological severity and with anatomical site of the tumor.

Conclusions
===========

An ideal marker predicting tumor prognosis should indicate tumor formation when present and should exclude such possibility on absence and to identify such a marker the five-year survival analysis is indispensable. Our previous study highlighted the importance of TP53 mutation when dealt with overall survival ranging from months to years. Following up on these patients, however, displayed that TP53 overexpression could not be held statistically significant over five-year survival. This could be due to the differing anatomical location of tumor in our patient set, the type of exposure and sample size. However, it is unlikely that a single tumor marker can predict tumor progression since the development and progression of a tumor is a cumulative response to various factors. Therefore, it is equally important to look at the status of other factors closely related to TP53. Nevertheless, the TP53 pathway is a very important one in head and neck squamous cell cancer pathogenesis and also potentially in its management. We believe that TP53 overexpression estimation may eventually prove useful as a routine component of tumor assessment along with tumor staging.
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